Dizal Pharmaceuticals

• Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)

  Phase 1, Not yet recruiting, 26 people, Oct 22, 2026

• Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

  Phase 2/3, Not yet recruiting, 880 people, Jul 17, 2026

• A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

  Phase 3, Recruiting, 218 people, Nov 18, 2025

• A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

  Phase 2, Recruiting, 66 people, Sep 4, 2025

• A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

  Phase 3, Recruiting, 250 people, Aug 24, 2025

• Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

  Phase 1/2, Recruiting, 220 people, Jul 23, 2025

• DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

  Phase 1/2, Recruiting, 180 people, Jul 17, 2025

• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

  Phase 1/2, Recruiting, 150 people, Jul 11, 2025

• DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

  Phase 2, Recruiting, 60 people, Feb 23, 2024

• Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

  Phase 1, Completed, 25 people, Jul 3, 2023

• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

  Phase 3, Active, not recruiting, 324 people, Dec 30, 2022

• Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

  Phase 1, Completed, 32 people, Aug 4, 2022

• Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

  Phase 1, Completed, 40 people, Jun 14, 2022

Sources: clinicaltrials.gov